tiprankstipranks
Trending News
More News >
Altamira Therapeutics (CYTOF)
OTHER OTC:CYTOF
US Market

Altamira Therapeutics (CYTOF) Income Statement

Compare
597 Followers

Altamira Therapeutics Income Statement

Last quarter (Q2 2023), Altamira Therapeutics's total revenue was CHF52.73K, a decrease of -63.73% from the same quarter last year. In Q2, Altamira Therapeutics's net income was CHF-2.71M. See Altamira Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
CHF 0.00CHF 305.62KCHF 63.88KCHF 174.47KCHF -56.00K
Gross Profit
CHF 0.00CHF -1.14MCHF -2.18MCHF 174.47KCHF -56.00K
Operating Expenses
CHF 6.54MCHF 24.99MCHF 14.92MCHF 5.46MCHF 7.26M
Depreciation and Amortization
CHF 5.92MCHF 118.89KCHF 76.36KCHF 20.04KCHF 30.82K
EBITDA
CHF -1.35MCHF -17.64MCHF -6.72MCHF -5.26MCHF -7.24M
Operating Income
CHF -5.92MCHF -26.13MCHF -17.10MCHF -5.28MCHF -7.26M
Other Income/Expenses
CHF -1.35MCHF -645.64KCHF -1.46MCHF -2.94MCHF 433.41K
Pretax Income
CHF -7.27MCHF -26.54MCHF -17.37MCHF -8.22MCHF -6.83M
Net Income
CHF -7.27MCHF -26.53MCHF -17.39MCHF -8.20MCHF -6.63M
Per Share Metrics
Basic EPS
CHF -14.81CHF -582.58CHF -525.13CHF -545.41CHF -455.96
Diluted EPS
CHF -14.80CHF -582.58CHF -525.13CHF -545.41CHF -455.96
Weighted Average Shares Outstanding
491.00K 45.54K 33.12K 15.04K 14.54K
Weighted Average Shares Outstanding (Diluted)
491.26K 45.54K 33.12K 15.04K 14.54K
Currency in CHF

Altamira Therapeutics Earnings and Revenue History